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ABSTRACT
Objectives: To estimate the budgetary impact of varenicline in the United
Kingdom (UK) in the ﬁrst 5 years after its introduction to the smoking-
cessation aid market, from the National Health Service (NHS) pharmacy
perspective.
Methods: The economic impact of varenicline to the national health
budget is estimated in a population of current, former, and new smokers.
The analyses are based on data from a variety of secondary sources
including national health data, clinical trials, and meta-analyses of
smoking-cessation aids. The number of patients seeking aid and the treat-
ment patterns are estimated using 2004 national health surveys, costs for
medications from national prescription drug pricing tariffs, and efﬁcacy of
the various smoking-cessation aids from clinical trial data. Sensitivity
analyses were performed to evaluate the impact of varying the patient
parameters and costs.
Results: Model estimates suggest that the budgetary impact of vareni-
cline would be £3.6 million in the second year after its introduction,
with a 95% conﬁdence interval of £0.63 to £7.2 million, and a resultant
increase of 0.05% to the total NHS pharmacy budget. The model pre-
dicts that the addition of varenicline to the market would result in an
additional 162,000 successful smoking-cessation attempts and 103,000
fewer smokers over 5 years, when compared to the world without
varenicline.
Conclusion: The introduction of varenicline is likely to result in greater
numbers of individuals succeeding at smoking cessation, with an approxi-
mately £3.6 million (0.05%) increase in the NHS pharmacy budget.
Keywords: budget impact analysis, NHS, smoking cessation, varenicline.
Introduction
Cigarette smoking is the leading preventable cause of death and
disease in the United Kingdom (UK), attributable for 114,000
deaths annually [1] and £1.5 billion in National Health Service
(NHS) expenditures (e.g., hospital, primary care, and pharma-
ceutical fees) [2]. In 2004, there were 12 million adult smokers in
the UK [3], and it is expected that one-half of the habitual
smokers within this group will die as a result of their addiction to
nicotine [4]. Although smoking increases the risk of developing a
wide array of diseases, the most fatal of the smoking-related
diseases are lung cancer, chronic obstructive lung disease (bron-
chitis and emphysema), and coronary heart disease [1].
Because of the economic burden that nicotine addiction
places on the UK health-care system, the Department of Health
allots an average of £46 million annually for the NHS Stop
Smoking Services [5]. Of the 600,000 smokers who enlisted the
aid of the Stop Smoking Services in 2005, 82% received some
form of nicotine-replacement therapy (NRT) and 5% received
bupropion [5]. NRT encompasses a wide variety of delivery
systems—including gums, lozenges, transdermal patches, nasal
sprays, and inhalers—but all share in common the objective of
alleviating the symptoms of nicotine withdrawal [6]. Although
the percentages of smokers who have attempted to quit smoking
has increased over the past 5 years [7], many smokers who try to
quit either fail to do so, or relapse soon after quitting. A 2006
report on smoking behavior in the UK showed that 80% of the
individuals who were smoking in 2005 had tried to quit at least
once at some point in the past [7]. For those smokers who had
failed to quit smoking, 32% had relapsed within 2 weeks of their
last cessation attempt.
Varenicline is a new oral medication with a novel mechanism
of action designed speciﬁcally for smoking cessation. In contrast
to NRT, in which small quantities of nicotine are provided to ease
nicotine withdrawal symptoms, varenicline partially activates the
a4b2 nicotinic acetylcholine receptors in the brain that are asso-
ciated with smoking, while simultaneously blocking nicotine
from binding with those same receptors. Consequently, vareni-
cline eases the craving and withdrawal symptoms associated with
smoking cessation, while also blocking the reward-based sensa-
tions that result from smoking a cigarette should a relapse occur
[8,9].
Although varenicline has the potential to improve smoking-
cessation initiatives in the UK, concerns may arise regarding its
impact on pharmacy budgets. Accordingly, we used modeling
techniques and data from a variety of secondary sources to
project the likely budgetary impact of varenicline from the UK
NHS pharmacy perspective.
Methods
Methodologic Overview
Estimation of budgetary impact of a new intervention involves
comparison of estimated health-care costs before versus after its
introduction—in effect, a contrast of the “world without” to the
“world with” the new intervention. The net difference in esti-
mated health-care costs between these two scenarios constitutes
the budgetary impact of the intervention. There are three main
components of a budgetary impact model: population, market-
place dynamics, and costs. The population component reﬂects
the number of individuals who are eligible to receive a new
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therapy. The marketplace dynamics component predicts market
uptake of the new therapy, along with consequent changes in
market shares of competing therapies and overall growth in the
market. The cost or economic component predicts changes in
costs and sometimes outcomes of care associated with the intro-
duction of the new therapy to the marketplace.
Model Structure
We developed a state-transition model reﬂecting relevant health
states for current and former adult smokers in the UK. The
model, illustrated in Figure 1, includes the following mutually
exclusive health states: current smokers eligible to quit using
prescription-based smoking-cessation therapy; current smokers
ineligible for such therapy; recent quitters (deﬁned as those who
had quit in the prior model cycle); sustained quitters (deﬁned as
those who quit in a prior model cycle and did not relapse in the
most recent cycle); former smokers (deﬁned as those who have a
history of smoking but had quit before entering the model) [10];
and individuals who have never smoked. The current smoker
eligible to quit state includes new smokers; current smokers who
are attempting or not attempting to quit; and recent quitters,
sustained quitters, and former smokers who relapsed in the pre-
vious model cycle. The model is estimated as a Markov process
over a period of 5 years, with a 6-month cycle length.
Individuals enter the model in one of three states: as a current
smoker eligible to quit, a former smoker, or as someone who has
never smoked. For convenience, we assume that all current
smokers enter the model eligible to quit and that no one begins
the model as a recent or sustained quitter (data limitations pre-
clude assignment of the UK population to these states). In any
given cycle of the model, current smokers eligible to quit may or
may not decide to do so, and those who do attempt to quit may
or may not receive prescription therapy. All those attempting to
quit may or may not be successful—those who are successful
transition to the recent quitter health state in the next model
cycle, while those who are not successful become current
smokers ineligible or eligible to quit depending on whether they
had or had not received prescription therapy in the current model
cycle. Because the cycle-length of the model is identical to the
UK’s 6-month waiting period between prescription-based quit
attempts, all current smokers ineligible to quit in a given model
cycle immediately become eligible in the next cycle.
All persons with a history of smoking—including recent quit-
ters, sustained quitters, and former smokers—are at risk of
relapse in each model cycle; those who do resume smoking
become current smokers eligible to quit in the next model cycle.
Recent quitters who do not relapse become sustained quitters in
the next model cycle, consistent with our previous deﬁnitions of
these health states. Finally, individuals who have never smoked
may begin to smoke in any given model cycle and in so doing
become current smokers eligible to quit in the next cycle.
Model Estimation
Model estimation involves predicting and tracking patients’ tran-
sitions across the health states over the 5-year time horizon of the
model, which was chosen to allow estimation of the budgetary
impact of varenicline over time, as its penetration into the mar-
ketplace takes effect. The smoking-cessation therapies that were
explicitly modeled include varenicline, bupropion, prescription
NRT, and nonprescription treatments. The nonprescription treat-
ment category includes both unaided cessation and over-the-
counter NRT.
Two inﬂows of new smokers are added to the current smoker
eligible to quit state in each year of the model, consisting of
17-year-old individuals [11] who turn 18 years old and are then
eligible for varenicline therapy (i.e., according to prescribing
instructions), and 18- to 24-year-old individuals who never
smoked and then start smoking. We added two inﬂows of new
smokers to the 18- to 24-year-old age group only, because
according to a 2004 UK household survey, 94% of male and
83% of female current or former smokers began smoking when
they were less than 25 years old [3]. The number of new smokers
in the 18- to 24-year-old age group was determined by multiply-
ing the annual probability of becoming a new smoker in that age
group [3] by the number of individuals who never smoked. Those
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Figure 1 Decision tree diagram of Markov states. Individuals enter the model in either the “Current smoker eligible to quit,” “Former smoker,” or “Never smoked”
state.
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individuals turning 25 years old in the model were no longer
eligible to become a new smoker.
Candidates for smoking-cessation treatment are determined
by multiplying age- and sex-speciﬁc prevalence rates for smoking
by the number of individuals in each age–sex group. The result is
then multiplied by the percentage of smokers attempting to quit
and the percentage electing to use pharmacologic therapy.
Finally, the number of smokers attempting to quit with pharma-
cologic therapy is then multiplied by the market share for each of
the smoking-cessation treatments, which yields the number of
individuals receiving each product in each model cycle.
We assumed that secular trends in the growth of the
smoking-cessation marketplace would continue throughout the
period of analysis and that the use of varenicline would result in
reduced market shares for existing products, including bupro-
pion and prescription NRT. That is, varenicline would take the
place of other prescription therapies and not cause an expansion
of the smoking-cessation aid marketplace. We based this assump-
tion on the “UK Smoking Related Behaviour and Attitudes
Survey” from 2004, which showed that the annual percentage of
smokers using prescription aids changed little after bupropion
was introduced to the smoking-cessation aid marketplace in
2000 [11].
Model Inputs
The total population and percentages of current and former
smokers in the model are contained in Table 1, and are stratiﬁed
by age and sex. Table 2 shows the clinical efﬁcacies for the
smoking-cessation treatments that were used in the model. The
efﬁcacies were obtained from clinical trial data and published
sources. Clinical efﬁcacy is deﬁned as carbon monoxide (CO)-
conﬁrmed continuous smoking abstinence through both 6 and 12
months. Because the prescription NRT formulations in the meta-
analyses showed similar clinical efﬁcacy to nonprescription NRT
formulations, an overall odds ratio for successful smoking ces-
sation was assumed [6,14], and we used pooled placebo rates to
calculate overall NRT efﬁcacy [8,9].
Three types of relapse rates were used within the model:
treatment-speciﬁc relapse rates, relapse among sustained quitters
who quit smoking during the model, and relapse among former
smokers who quit smoking at some point before the start of
the model. The clinical efﬁcacies were used to calculate the
treatment-speciﬁc relapse rates in the model. Each relapse rate
was calculated as the difference between the 6- and 12-month
efﬁcacies, divided by the 6-month efﬁcacy. The relapse rates for
the sustained quitters and the former smokers were estimated
separately, because relapse probability varies with the duration of
smoking abstinence. We used a 6-month relapse rate of 3.3% for
sustained quitters, and 0.6% for former smokers [10].
With respect to treatment costs, a “full course” of treatment
is typically 9 to 12 weeks in length, and costs £165.66 for
varenicline [17], £81.56 for bupropion [18], and £115.81 for
NRT [18]. Nevertheless, the ﬁrst prescription in the UK only
covers 2 to 4 weeks of smoking-cessation treatment. Conse-
quently, a “partial course” cost was calculated for those patients
who failed at their attempt to quit smoking before they could
start a second prescription. The cost for a partial course of
treatment was calculated as £28.23 for varenicline, £40.78 for
bupropion, and £39.54 for NRT. All costs used in the analysis are
expressed in 2006 pounds sterling.
The top half of Table 3 contains the percentage of smokers
who attempt to quit smoking annually. In addition, 25% of the
smokers who will attempt to quit smoking in each year of the
model will use a pharmacological treatment. The bottom half of
Table 3 contains the market share projections for each of the
smoking-cessation treatments, in each year of the model. We
assumed that bupropion and prescription NRT are the only
Table 1 Total population and smoking status stratiﬁed by age group and
sex
Male Female
Total population [12]
18–24 years old 2,723,100 2,642,100
25–44 years old 8,506,800 8,622,600
45–64 years old 7,170,400 7,368,000
65 years old 4,091,100 5,488,800
Current smokers [13]
18–24 years old 25.00% 29.00%
25–44 years old 31.11% 27.46%
45–64 years old 22.16% 22.62%
65 years old 8.74% 10.94%
Former smokers [13]
18–24 years old 5.00% 7.00%
25–44 years old 17.75% 17.08%
45–64 years old 36.62% 26.86%
65 years old 58.10% 31.58%
Table 2 Sustained abstinence rates for the smoking-cessation treat-
ments that were used in the model
Smoking-cessation treatment Abstinence rate % (SD)
Varenicline [8,9]
6 months 29.8 (6.12)
12 months 22.5 (4.88)
Bupropion [8,9]
6 months 20.5 (3.33)
12 months 15.7 (3.01)
Prescription NRT [6,8,9,14]
6 months 19.1 (1.05)
12 months 15.5 (0.79)
Nonprescription NRT [6,8,14]
6 months 19.1 (1.05)
12 months 15.5 (0.79)
Unaided cessation [15,16]
6 months 6.0 (0.60)
12 months 5.0 (0.50)
NRT, nicotine-replacement therapy; SD, standard deviation.
Table 3 Marketplace dynamics in each of the 5 years of the model
2007 2008 2009 2010 2011
Percentage of smokers
attempting to quit
annually [11]
18–24 years old 21.8% 22.6% 23.4% 24.2% 25.1%
25–44 years old 35.2% 36.6% 37.9% 39.2% 40.6%
45–64 years old 24.9% 25.8% 26.8% 27.7% 28.6%
65 years old 13.5% 14.0% 14.5% 15.0% 15.5%
Market shares without
varenicline*
Bupropion 4.36% 4.54% 4.71% 4.89% 5.06%
NRT 95.64% 95.46% 95.26% 95.11% 94.94%
Market shares with
varenicline*
Varenicline 11.09% 16.01% 20.94% 25.86% 30.79%
Bupropion 4.00% 3.60% 3.21% 2.81% 2.42%
NRT 84.91% 80.38% 75.85% 71.33% 66.80%
*Pﬁzer, Inc. market projections.
NRT, nicotine-replacement therapy.
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available smoking-cessation treatments on the market in the
“world without” varenicline. Varenicline is added as a treatment
in the “world with” scenario.
Analyses
Budgetary impact was calculated by taking the difference in
aggregate drug costs in the “world without” and the “world
with” varenicline. The per-treatment-success budgetary impact
was calculated by dividing the aggregate drug costs by the
number of treatment successes.
One-way sensitivity analyses were performed to assess the
robustness of model results to plausible variation in parameters.
Where possible, the ranges of selected model parameters (e.g.,
abstinence rates) were varied according to published sources
[6,11,13], otherwise parameters were varied through a range of
75% to 125% of the base-case estimate.
To assess uncertainty, probabilistic sensitivity analyses were
performed on the budgetary impact in the second year of the
model to allow enough time for market penetration yet not
relying heavily on model assumptions and extrapolations. The
drug-speciﬁc abstinence rates, and relapse probabilities, were
assumed to have a beta distribution that was based on the point
estimates, and the standard deviations of the estimates, where
available. A random number generator was used to draw a set of
parameter values from these distributions; the parameter set was
then inserted into the model and the budgetary impact recalcu-
lated in the usual manner. The process of drawing parameters
and running the model was repeated 1000 times.
Results
Budgetary Impact Analysis
The overall budgetary impact is estimated to be £2.5 million in
2007, £3.7 million in 2008, £4.8 million in 2009, £5.9 million in
2010, and £7.0 million in 2011. The per-treatment-success bud-
getary impact is estimated to be £120.18 in 2007, £120.48 in
2008, £120.76 in 2009, £121.04 in 2010, and £121.31 in 2011.
The budgetary impact data for overall and per treatment success
are presented in Table 4.
Annual prescription costs for smoking-cessation treatments
in the “world without” varenicline were estimated to be £79.8
million in 2007, £83.9 million in 2008, £85.1 million in 2009,
£86.3 million in 2010, and £87.3 million in 2011. Annual pre-
scription costs in the “world with” varenicline were estimated to
be £82.3 million in 2007, £87.6 million in 2008, £90.0 million in
2009, £92.2 million in 2010, and £94.3 million in 2011. The
increased costs in the “world with” varenicline are due to the
higher costs of varenicline relative to other smoking-cessation
aids, the increasing numbers of current smokers attempting to
quit [7,11], and the increasing numbers of patients who take
varenicline instead of other prescription smoking-cessation aids.
Treatment with smoking-cessation aids in the “world with”
varenicline yielded more than 2.7 million quitters (i.e., 12
months of sustained smoking abstinence), and approximately 3.7
million treatment successes (i.e., 6 months of sustained smoking
abstinence) by the end of the 5-year model. Furthermore, the
addition of varenicline to the smoking-cessation aid market
resulted in an additional 162,000 successful smoking-cessation
attempts and 103,000 fewer smokers in the “world with” versus
the “world without” varenicline.
Sensitivity Analyses
A one-way sensitivity analysis was conducted on model param-
eters to assess robustness. The following parameters were
included in the analysis: treatment success and failure costs for
varenicline, NRT, and bupropion; 6- and 12-month abstinence
rates for varenicline, NRT, and bupropion; the relapse probabili-
ties for recent quitters and former smokers; percentage of indi-
viduals taking prescription treatment; and the percentage of
individuals in each age group attempting to quit. The one-way
sensitivity analysis showed that the budgetary impact estimate
was most sensitive to variations in the costs of varenicline and
NRT, and least sensitive to NRT efﬁcacy (Fig. 2).
To assess uncertainty, a probabilistic sensitivity analysis was
performed on the budgetary impact in the second year of the
model and suggests that the mean budgetary impact would be
£3.6 million, with a 95% conﬁdence interval of £0.634 to £7.2
million.
Discussion
The overall budgetary impact of varenicline was estimated to be
£2.5 million in the ﬁrst year after introduction, £4.8 million in
2009, and £7.0 million in 2011 for the UK. The increase in the
overall budgetary impact of varenicline across the 5-year time
horizon of the model is due to the higher cost of varenicline,
when compared to other smoking-cessation treatments, the
increasing number of smokers trying to quit, and the increasing
numbers of individuals taking varenicline. Although the overall
budgetary impact increased from 2007 to 2011, the per-
treatment-success budgetary impact changed very little across the
5-year time horizon (e.g., £120.18 in 2007, £120.76 in 2009, and
£121.31 in 2011).
In spite of the robustness of the model in predicting budgetary
impact, there are some limitations. Our model assessed cost and
impact on the NHS pharmacy budget. Costs incurred by other
payers such as employers and patients are excluded, although
they may impact the utilization of certain smoking-cessation
therapies. Also, no cost offsets are included from reduced medical
care for not smoking, which could decrease the budgetary impact
of the NHS as a whole. Although not likely substantial in the
short run, these cost offsets would certainly accumulate over time
because of avoidance of costly and deadly smoking-related ill-
nesses, such as lung cancer, chronic obstructive pulmonary
disease, and cardiovascular disease. In fact, Rasmussen et al. [19]
have estimated the direct lifetime health-care cost-savings to be
about €10,000 on average, or about £6,700, for a moderate
smoker who quits smoking at the age of 35 years. The savings
were based on hospital, physician, and drug costs for the treat-
ment of various smoking-related diseases (e.g., cancer, vascular,
Table 4 Overall and per treatment success budgetary impact
Budgetary impact
Year
2007 2008 2009 2010 2011
Overall (£ millions) 2.48 3.63 4.68 5.71 6.73
Per treatment success (£) 120.18 120.48 120.76 121.04 121.31
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respiratory). Rasmussen’s estimates were based on the 1999 data
collected in Denmark, and rising health-care costs could result in
even larger lifetime savings.
Finally, our estimates of the number of smokers who are
attempting to quit and using pharmacological treatment are
based on national surveys. Although the 2004 “National Health
Survey for England” [13] and the 2004 “Smoking Related
Behaviour and Attitudes Survey” [11] are well-documented and
established, these may overestimate the actual numbers and per-
centages of smokers attempting to quit. This is because survey
participants may sometimes exhibit what is referred to as “Evalu-
ation Apprehension” [20], where participants respond in such a
way as to put themselves in the best light (e.g., saying that they
intend to quit smoking). A resulting decrease in the number of
individuals attempting to quit would decrease the budgetary
impact.
Our analysis sheds light on the probable impact of the intro-
duction of varenicline in the UK. Our model suggests that intro-
duction of varenicline will likely result in a greater number of
smoking-cessation treatment successes, and thus fewer smokers,
when compared to traditional smoking-cessation therapies such
as NRT. A reduction in the number of smokers would result in a
reduction in the medical costs that are linked to smoking behav-
iors. The introduction of varenicline in the UK would only
increase the UK pharmacy budget by 0.05%, based on the 2005
to 2006 Family Health Service drugs bill expenditure of £7,235
million that was reported in the 2007 UK Department of Health
Report [21].
As experience with varenicline in the UK accumulates, addi-
tional data on its ﬁnancial impact on NHS budgets will become
available. Until then, our projections of budgetary impact may be
of use to NHS administrators, formulary committee members,
clinicians, patients, and others interested in the economics of
smoking cessation in the UK.
Source of ﬁnancial support: Pﬁzer Inc., New York, NY, USA.
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